Specimen Return Information Form for NeXT Dx Test
Specimen Return Information Form | NeXT Dx Test
Specimen Return Information Form | NeXT Dx Test
SHERPA™ Bioinformatics Engine Systematic HLA Epitope Ranking Pan Algorithm Technologies for neoantigen discovery are critical for developing personalized cancer vaccines and neoantigen-based biomarkers. Precision neoantigen discovery entails the comprehensive detection of tumor-specific genomic variants and accurate prediction of MHC presentation of epitopes originating from such variants. The ImmunoID NeXT [...]
Powered by our ACE Technology, our DNA Assays provide more uniform coverage at high depths than standard assays. Specifically, our ACE-enabled assays outperform conventional exome assays by enhances coverage across coding regions and supplementing more complex areas in the genomic architecture such as GC-rich content. The Personalis solution provides targeted sequencing to augment coverage gaps [...]
Our patented ACE™ (Accuracy and Content Enhanced) Technology is the foundation of ImmunoID NeXT and all proprietary Personalis products. ACE improves processes from nucleic acid preparation, to sequencing, to analytics for superior sequencing results. Nucleic Acid Extraction and Sample Preparation Personalis has developed protocols to overcome the challenges of working with difficult samples including FFPE, [...]
HLA binding is currently the most well-established criteria for ranking neoantigen candidates. Recent advances in training data generated from mass spectrometry provide a larger dataset of peptide binders and non-binders for individual HLA alleles. This new binding data takes two important additional components into consideration: cleavage and transportation, which are critically important for presentation assessment. [...]
NeoantigenID Technologies for neoantigen discovery are critical for the development of personalized cancer therapies and neoantigen-based biomarkers. Precision neoantigen discovery entails comprehensive detection of tumor-specific genomic variants and accurate prediction of MHC presentation of epitopes originating from such variants. Our ImmunoID NeXT Platform® enables a comprehensive survey of putative neoantigens by combining highly sensitive exome- [...]
NeXT Liquid Biopsy™ It’s Time to Think About More. High-Performance Whole Exome Sequencing from Plasma. Highlights Comprehensively profile the tumor, exome-wide Combined with ImmunoID NeXT™, assess tumor heterogeneity, monitor response to therapy, and interrogate mechanisms of resistance Profile with ImmunoID NeXT, Monitor with NeXT Liquid Biopsy Leverage somatic variant [...]
Stephen Moore joined Personalis as General Counsel in April 2020, with more than twenty years in-house legal experience at advanced genomics companies. Prior to joining Personalis, he was General Counsel at Pacific Biosciences, a publicly listed company and pioneer in the field of single molecule, long read DNA sequencing, where he worked for over a [...]
Personalis NeXT Dx™ Test Increasingly, oncologists and pathologists are utilizing information on genomic alterations in solid tumors, such as lung, colon, breast, melanoma, and prostate cancers, to help guide and optimize therapeutic options for patients including enrolling into cancer clinical trials. The Personalis NeXT Dx™ Test provides clinicians with a comprehensive [...]
Specimen Preparation Guide for Clinical Use: FFPE To ensure submitted specimens yield sufficient amounts of extracted DNA and/or RNA for sequencing and analysis, we have provided the following guidelines below for solid tumors. Unacceptable specimens include hematolymphoid malignancies or decalcified bone. FFPE — Specimen Preparation Guidelines for FFPE preparation: [...]